Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

It won’t get quite the work-on-Thanksgiving welcome that the Covid-19 jab received, but another Pfizer vaccine is headed to the FDA, where it will receive a speedy review.

Pfizer announced Wednesday that an application for its new pneumococcal vaccine, 20vPnC, has been accepted and granted priority review at the agency, setting up a decision by June of next year.